GeneXpert test cartridge being used to test a sample of suspected TB in MSF’s lab at Bangassou Hospital, Central African Republic, 2017.

Photo credit: Borja Ruiz Rodriguez/MSF

Time for $5

The GeneXpert diagnostic testing technology from the US corporation Cepheid, and its parent company Danaher, has revolutionised rapid, accurate diagnosis of tuberculosis (TB) and other diseases, since entering the market in 2010. Yet, due to the high cost of the GeneXpert test cartridges, many countries are not able to scale up testing for all people who need lifesaving diagnosis and subsequent treatment.

Open letter to governments blocking the proposal to remove monopolies on COVID-19 medical tools during the pandemic

Read, watch, share

From TRIPS to PPR: Addressing Intellectual Property Barriers on Lifesaving Medical Products

MSF welcomes pro-access recommendations in European Parliament COVID report

Africa-South Korea Roundtable: Working Together on Local Production of Diagnostics

Principles for Access to Multi-disease Molecular Diagnostics

MSF responds to BioNTech announcement that it will set up first “BioNTainers” by end of 2022

WTO adopts inadequate text, not a real Waiver on COVID monopolies

Inability to agree a real pandemic intellectual property Waiver at WTO is a devastating global failure for people the world over

Trade Ministers at WTO should not accept current draft of Ministerial Decision on TRIPS

No Patents, No Monopolies in a Pandemic

Monopolies are often an obstacle between people and the lifesaving health tools they need. Patents and other exclusivities limit supply and keep prices high.

The COVID-19 pandemic has shown we need new rules that can help every country address the fast-growing medical needs during a major global health crisis.

Over 100 countries at the World Trade Organization (WTO) supported a proposal to temporarily waive patents, trade secrets and other intellectual property (IP) on all COVID-19 medical tools.

Latest news

MSF welcomes pro-access recommendations in European Parliament COVID report

#ShareTheTech - why pharma must share the mRNA vaccine technology

WTO adopts inadequate text, not a real Waiver on COVID monopolies

MSF responds to BioNTech announcement that it will set up first “BioNTainers” by end of 2022

Inability to agree a real pandemic intellectual property Waiver at WTO is a devastating global failure for people the world over